Auto-Injector Market Outlook 2031
The global auto-injector market size was valued at USD 2.82 Billion in 2022 and is likely to reach USD 12.51 Billion by 2031, expanding at a CAGR of 18% during the forecast period, 2023–2031. The market growth is attributed to the rising need for auto-injectors among allergic and diabetic patients.
Autoinjectors are self-injectable medical devices. They are considered important medical devices in the modern healthcare sector. These devices can deliver drugs through the intramuscular route or subcutaneous and includes prefilled cartridges or auto-injector syringes, which are driven by a spring system. For instance, adrenaline auto injectors deliver an adequate dosage of epinephrine or adrenaline.
Improved patient compliance, easy self-administration, dosage accuracy, and reduced anxiety are the major benefits of automatic injector devices. In emergency conditions including high migraine, anaphylaxis, status epileptics, or chronic conditions self-administration can be done by using an automatic injector device.
There are several advantages of auto injectors and they work with different principles. Some of the autoinjector types are easy push-on-skin devices to fully automated button activated technologies.
Autoinjectors devices are easy to use and efficient in administering several types of drugs such as monoclonal antibodies, disease-modifying drugs, and antidotes for toxic and poisonous chemicals. In addition, these devices are known for their patient compliance as drugs can be self-injected by patients.
COVID-19 Impact on Auto Injector Market
The market report finds that the COVID-19 pandemic has positively impacted the global market, due to the increasing demand for vaccines and drugs. An increasing number of disease-specific vaccines is boosting the demand for self-injectable drug delivery such as auto injector syringes and needles in recent years.
The market witnessed a small setback as the pandemic directly affected the production, and demand for drugs, which resulted in financial losses to firms operating in the medical device manufacturing and supply industry, and others.
Several countries such as India, Saudi Arabia, China, Egypt, and others faced problems in relation to the transportation of drugs or vaccines from one place to another.
For better injection speed and treatment anxiety management, advanced innovative technologies are available in the auto-injector market. Rheumatoid arthritis, diabetes, and Crohn’s disease patients are dependent on prefilled syringes, due to the usage of auto injectors and to control the patient’s diseases at home. As the home-based medical solution witnessed a considerable rise, it also resulted in market growth during the pandemic.
Auto Injector Market Dynamics
The research report presents a complete market overview by providing detailed information about the current market trends, existing drivers, growth opportunities and potentials, and emerging challenges.
The global auto injector market report has up-to-date insights about market scenarios that can shape the overall market performance and output during the forecast period, 2023 to 2031.
Key Trends
The number of patients with chronic diseases is increasing, which is one of the key trends in the global auto injector market. The importance of injections in some allergic cases is increasing the demand for the market.
In addition, the adoption of auto-injectors is also increasing significantly in several countries, due to chronic disease. The cases of chronic disease increasing rapidly worldwide. These cases have affected the quality of life for numerous citizens across the world.
Poorly managed chronic diseases are causing a major impact on the well-being of society. Additionally, these diseases are triggering early retirements, reductions in wages, decrease labor productivity, and others.
Such a rising prevalence of chronic disease and a growing number of chronic patients preferring auto-injectors due to convenience and easy accessibility is driving the demand for the product in the global market.
Drivers
The prevalence of anaphylaxis is increasing, which is anticipated to boost the global auto injector market during the forecast period. Anaphylaxis is dangerous and is a potentially life-threatening allergic reaction occurring in patients due to drugs, Hymenoptera strings, food, and latex.
Anaphylaxis allergy type is common and occurs in one individual out of every 1000 cases in the population as reported by the NICE study.
During anesthesia, anaphylaxis occurs in one patient out of every 2000 cases across the globe. In the future, patients may choose an alternative to anesthesia, if a more secure combination of drugs can be identified. In 2019, the European Journal of Allergy and Clinical Immunology reported that globally several children are affected by anaphylaxis.
Restraints
The availability of different drug delivery alternatives is the major restraining factor that can hamper global market expansion. Outdated injectables with syringes and vials are more painful modes of drug delivery.
In several health cases, patients and healthcare providers are preferring alternative drug supply routes such as nasal, oral, and topical routes. The convenient, safe, easy-to-use, acceptable, and cost-effective solutions are preferred for oral routes.
Needle-free drug delivery as jet injectors is likely to restrain the growth of the market. Needle-free drug devices do not cause anxiety in patients, which is a hindrance to the increasing inclination toward injectable drug treatments. Most children have needles fear, while estimates are around 20-50% in adolescents and 20-30% in young adults.
Patients who are suffering from rheumatoid arthritis, diabetes, improve hormone deficiency, and others need weekly injection therapy by using auto-injector. The needle anxiety or fear is likely to restrain the growth of the auto injector market.
Opportunities
The preference for home-based medical solutions or treatments has increased significantly due to limited visits to hospitals and physical contact restrictions. The COVID-19 pandemic protocols shifted people’s preference for a safe environment for medical treatments, which limited their visits to hospitals.
Visiting hospitals and clinics for non-emergency conditions prevent both transmissions of the virus and make sure that healthcare institutions are not overwhelmed.
Most of the patients prefer home-use auto injectors devices as they are suffering from various diseases such as allergies and chronic illnesses. The rise of home-based treatments is expected to be a significant opportunity for global market growth.
This is also protecting the high-risk population from the virus during the pandemic and is likely to increase the growth opportunity for automatic injector devices.
Autoinjectors are developed to support the viscosity and concentration of drugs, which reduces the administration frequency and increase constancy to recommended drug protocols. These factors are expected to increase the growth opportunity in the auto injectors market during the projection period.
Scope of Auto Injector Market Report
The global auto injector market research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Auto Injector Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type (Reusable Auto Injectors and Disposable Auto Injectors), Application (Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Diabetes, and Others), End-user (Hospitals & Clinics, Homecare Settings, and Others), and Route of Administration (Intramuscular and Subcutaneous)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Auto Injector Market Size and Analysis, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Amgen Inc.; AbbVie Inc.; SHL Medical AG; Union Medio Inc.; Emergent; Mylan N.V.; Jabil Inc.; Johnson Medtech; West Pharmaceutical Services; Antares Pharma; Ypsomed Holding; Owen Mumford; Teva Pharmaceuticals USA. Inc.; Consort Medical, Plc.; AstraZeneca; Union Medico Inc.; Gerresheimer AG; Stevanato Group; and Others.
|
Auto Injector Market Segment Insights
What Key Factors Contribute to the Rapid Expansion of the Disposable Auto Injectors Segment?
Based on type, the global auto injector market is divided into reusable autoinjectors and disposable auto injectors. The disposable auto injector segment is anticipated to hold a considerable market share in the global auto injector market during the forecast period.
The demand for disposable auto injectors devices is increasing due to factors such as low cost, ease of use, and inclusion of built-in glass syringes. The demand for disposable auto injectors in emerging economies such as India, China, and Japan is rising, due to the increasing prevalence of rheumatoid arthritis and diabetes diseases.
The reusable autoinjector segment is also expected to grow at a significant pace during the forecast period in the global market. Reusable autoinjectors are available in two forms such as empty and pre-filled. Prefilled auto injectors come with filled barrels that contain therapeutic and are easy to use.
What are Major Reasons for High Revenue Generation in the Rheumatoid Arthritis Segment?
On the basis of application, the market is segregated into anaphylaxis, multiple sclerosis, rheumatoid arthritis, diabetes, and others. The rheumatoid arthritis segment is anticipated to account for the largest market share during the forecast period, due to the increasing prevalence of rheumatoid diseases.
Rheumatoid arthritis characterizes most generous of autoimmune arthritis and this disease affects up to 1% of the world’s population. Around 75% of rheumatoid arthritis disease affects females as compared to males.
The anaphylaxis segment is expected to expand at a significant growth rate during the forecast period. A large percentage of anaphylactic diseases are caused by allergic reactions to foods, drugs, latex, and insect stings, which is boosting the anaphylaxis segment.
Anaphylaxis is a life-threatening and critical allergic reaction and can occur within a minute. Increasing anaphylactic hospitalizations due to the cause of anaphylaxis and the trigger. According to the Asthma and Allergy Foundation of America, allergy is a common health issue that is affecting children, especially in the US.
Which Major Factors Influence the Significant Growth of the Home Care Segment?
Based on end-user, the global auto injector market is segmented into hospitals & clinics, homecare settings, and others. The home care segment is anticipated to hold the major market share in the global auto injectors market during the forecast period.
The patient preference for home care therapeutic treatments is increasing substantially, owing to the increasing popularity of cost-effective healthcare, rapid growth in the elderly population, telehealth, and other factors. Additionally, the number of chronic illnesses is rising, including rheumatoid arthritis multiple sclerosis. It emphasizes the increasing demand for home-based treatment solutions.
The hospitals & clinics segment is expected to register a considerable CAGR during the forecast period. An increasing number of people are suffering from multiple sclerosis and allergy. Multiple sclerosis impacts around 400,000 people in the US and globally it impacts around 2.5 Million people. Medical reimbursement and healthcare facilities for auto injector devices in emerging economies are the major factors driving the growth of the market.
What are Main Aspects of Boosting the Subcutaneous Segment?
On the basis of the route of administration, the market is segmented into intramuscular and subcutaneous. The subcutaneous segment is expected to hold the largest market share in the coming years. The subcutaneous injection involves a small needle under the skin to deliver a drug or medicine to the fatty tissue.
This subcutaneous injection doesn’t deliver a drug straight into the body. Patients use auto injectors to provide subcutaneous medicines such as diabetes, migraine, anaphylaxis, multiple sclerosis, rheumatoid arthritis, and cancer. The number of product approvals for chronic diseases is increasing, which is one of the major factors driving the growth market.
The intramuscular auto injector segment is the second largest segment in the global market. The intramuscular injection is used in specifically selected muscles and installs drugs into the depth of the muscles. This allows the drugs to be absorbed into the blood quickly. Intramuscular injections are common in modern drug treatment.
Regional Analysis
In terms of region, the global auto injector market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to hold the largest market share during the forecast period, owing to the continuous technological advancements in medical devices.
An increasing number of people with diabetes and anaphylaxis diseases in North America boosts the product demand in the region. In addition, a high prevalence of chronic diseases such as cancer fuels the market growth in the region.
According to the Centers for Disease Control and Prevention (CDC), in the US around 37 million people are suffering from diseases such as diabetes and anaphylaxis. Several peoples highly depend on auto-injectors for their insulin shots, to manage their blood sugar levels.
Asia Pacific is expected to have a significant market share during the forecast period. Investments in the healthcare industry are increasing which is expected to boost the production of the global auto injector market in the region.
The presence of diabetic patients and anaphylaxis is rising due to food allergies in developing countries such as China, India, Japan, and others parts, which is expected to boost the global market in the region.
Europe is expected to grow at a CAGR of 16.33% in the global market during the forecast period. The rate of chronic disease rising in the region. In addition, increasing investments and funds by the key players are the major factors boosting the market growth in the region.
Segments
The global auto injector market has been segmented on the basis of
Type
- Reusable Auto Injectors
- Disposable Auto Injectors
Application
- Anaphylaxis
- Multiple Sclerosis
- Rheumatoid Arthritis
- Diabetes
- Others
End-user
- Hospitals & Clinics
- Homecare Settings
- Others
Route of Administration
- Intramuscular
- Subcutaneous
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Amgen Inc.
- AbbVie Inc.
- SHL Medical AG
- Union Medio Inc.
- Emergent
- Mylan N.V.
- Jabil Inc.
- Johnson Medtech
- West Pharmaceutical Services
- Antares Pharma
- Ypsomed Holding
- Owen Mumford
- Teva Pharmaceuticals USA. Inc.
- Consort Medical, Plc.
- AstraZeneca
- Union Medico Inc.
- Gerresheimer AG
- Stevanato Group
- Others
Competitive Landscape
The competitive landscape of the global auto injector market report provides key insights into the growth strategies and development initiatives implemented by the key players in the market.
Key players competing in the global auto injector market are Amgen Inc.; AbbVie Inc.; SHL Medical AG; Union Medio Inc.; Emergent; Mylan N.V.; Jabil Inc.; Johnson Medtech; West Pharmaceutical Services; Antares Pharma; Ypsomed Holding; Owen Mumford; Teva Pharmaceuticals USA. Inc.; Consort Medical, Plc.; AstraZeneca; Union Medico Inc.; Gerresheimer AG; Stevanato Group; and Others.
Some of these major companies adopted various business development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production capacity expansion to expand their consumer base and enhance their market share.
- In September 2021, Owen Mumford launched a new 2-step single-use auto injector platform Aidaptus. Aidaptus is a spring-powered 2-step, single-use auto injector with a versatile design that accommodates 1ML and 2.25 ML auto injector syringes in the same device.
- In May 2022, Jabil Healthcare launched the Qfinity auto injector platform, a reusable, simple, and modular solution for subcutaneous (SC) drug self-administration. It supports the emerging prioritization of sustainable drug delivery within the pharmaceutical industry. The Qfinity auto injector platform is convertible with broad technical specifications for drug volumes and drug viscosities.
- In May 2022, Stevanato Group S. p. A. signed an agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for an Aidaptus auto injector. Stevanato Group is a global provider of drug delivery, drug containment, and diagnostic solutions to the pharmaceutical, life sciences, and biotechnology industries.
- In May 2020, the Kaleo Company relaunched the ALLERJECT auto injector for Canada. The auto injectors are available for Canadians at risk for Anaphylaxis.
- In August 2020, Antares Pharma, Inc., announced an agreement with Lunatus Global Medical Supplies to distribute and promote the sale of XYOSTED in Saudi Arabia and the United Arab Emirates (UAE).
Request For Customization
Enquiry Before Buying
Speak With Analyst
